ABSTRACT
Finding the optimal combination of drugs in the correct dosages, which requires careful monitoring over time, is key to slowing the disease process and prolonging life. For most patients, treating heart failure involves correcting underlying left ventricular dysfunction, thereby slowing the remodeling process.
Footnotes
↵* The author has received grant support from Novartis Pharmaceuticals, has served as a consultant for Forest Pharmaceuticals, and is on the speakers’ bureau for AstraZeneca, Merck, Novartis Pharmaceuticals, Pfizer, Solvay, and Wyeth-Ayerst. This paper discusses therapies that are not approved by the US Food and Drug Administration for the use under discussion.
- Copyright © 2002 The Cleveland Clinic Foundation. All Rights Reserved.